Regeneron Pharmaceuticals
REGN
742.12
+3.40
+0.46%
Regeneron Pharmaceuticals
US · REGN
#285 by market cap
Listed 1970
742.12
+3.40
+0.46%
Live - 5344 symbols - heartbeat 80s ago
· 2026-10-08 05:13
Pre-market
742.00
-0.02%
After-hours
742.12
0.00%
Overnight
741.93
-0.03%
- Market cap
- 76.40B
- P/E (TTM)i
- 18.36
- P/Bi
- 2.41
- EPSi
- 41.48
- Div yieldi
- 0.49%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on REGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 11 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 94.17% +0.35pp
- Institutions
- 1,667 -11
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund78.75%
Hedge Fund4.61%
Public Company4.13%
Individual/Insider3.83%
Government Pension Fund2.56%
Private Company1.87%
Sovereign Wealth Fund1.27%
Insurance Company0.42%
Family Office/Trust0.20%
Other2.37%
Top holders
BlackRock
9.13%
Vanguard Capital Management, LLC
7.20%
Dodge & Cox
4.88%
State Street Global Advisors
4.84%
Invesco Capital Management LLC
3.24%
Other
70.71%
Vanguard Portfolio Management, LLC
3.18%
J.P. Morgan Asset Management, Inc.
3.17%
Geode Capital Management, LLC
2.63%
Leonard Schleifer
2.42%
Putnam LLC
2.31%
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 23 sells
| Name | Role | Stake |
|---|---|---|
| Leonard Schleifer | Co-Founder, President, CEO & Co-Chairman | 2.42% |
| George Yancopoulos | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1.17% |
| Andrew Murphy | Executive Vice President of Research | 0.05% |
| Joseph LaRosa | General Counsel | 0.05% |
| Daniel Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 0.04% |
| George Sing | Independent Director | 0.03% |
| Christopher Fenimore | Senior VP, Head of Accounting & Controller | 0.02% |
| Marion McCourt | Executive Vice President of Commercial | 0.01% |
| Michael Brown | Independent Director | 0.01% |
| Robert Landry | Chief Financial Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-02 | Marion McCourt | Executive Vice President of Commercial | Automatic Disposition | -2,346 | $850.00–857.39 |
| 2026-09-02 | Marion McCourt | Executive Vice President of Commercial | Intent to Sell (Form 144) | -1,131 | $857.00 |
| 2026-09-01 | Marion McCourt | Executive Vice President of Commercial | Intent to Sell (Form 144) | -1,215 | $850.00 |
| 2026-09-01 | Kathryn Guarini | Independent Director | Derivative Exercise and Sale | -400 | $719.37–850.00 |
| 2026-08-18 | Joseph LaRosa | General Counsel | Derivative Exercise and Sale | -9,019 | $381.92–830.15 |
| 2026-08-18 | Joseph LaRosa | General Counsel | Derivative Exercise and Retained | +3,263 | $381.92 |
| 2026-08-17 | Christopher Fenimore | Senior VP, Head of Accounting & Controller | Derivative Exercise and Sale | -4,599 | $381.92–813.47 |
| 2026-08-17 | Christopher Fenimore | Senior VP, Head of Accounting & Controller | Derivative Exercise and Retained | +1,684 | $381.92 |
| 2026-08-09 | Huda Zoghbi | Independent Director | Derivative Exercise and Sale | -800 | $376.69–800.00 |
| 2026-08-09 | Kathryn Guarini | Independent Director | Derivative Exercise and Sale | -400 | $719.37–800.00 |
| 2026-07-01 | Arthur Ryan | Independent Director | Automatic Disposition | -200 | $650.15 |
| 2026-04-30 | Arthur Ryan | Independent Director | Open Market Disposition | -100 | $701.76–714.13 |
| 2026-03-31 | Arthur Ryan | Independent Director | Automatic Disposition | -100 | $771.32–779.71 |
| 2026-03-01 | Arthur Ryan | Independent Director | Automatic Disposition | -100 | $777.46–789.28 |
| 2026-02-18 | Huda Zoghbi | Independent Director | Derivative Exercise and Sale | -1,638 | $376.69–790.00 |
| 2026-02-08 | Arthur Ryan | Independent Director | Automatic Disposition | -100 | $775.63–787.82 |
| 2026-02-08 | Jason Pitofsky | Vice President | Automatic Disposition | -1,036 | $778.35–785.72 |
| 2026-02-08 | Jason Pitofsky | Vice President | Derivative Exercise and Sale | -1,000 | $492.00–778.35 |
| 2026-01-06 | Bonnie Bassler | Independent Director | Derivative Exercise and Sale | -1,500 | $374.12–800.00 |
| 2026-01-01 | Christine Poon | Lead Independent Director | Other Acquisition | +155 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:13:24 · For reference only, not investment advice and not tailored to your situation.